Floatz logo

FILGRASTIM

Male Breast Cancer

University of Washingtonprotein_peptidePhase 2Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Male Breast Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
University of California, Irvine
Phase 2BBB
Inno-206
National Cancer Institute (NCI)
Phase 2BBB
Cyclophosphamide
Wake Forest University Health Sciences
Phase 2BBB
Cediranib
University of Chicago
Phase 2BB
Capecitabine
Jonsson Comprehensive Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →